Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort
Félix Gutierrez,Sergio Padilla,Mar Masiá,José A Iribarren,Santiago Moreno,Pompeyo Viciana,Leopoldo Muñoz,José L Gómez Sirvent,Francesc Vidal,José López-Aldeguer,José R Blanco,Manuel Leal,María Angeles Rodríguez-Arenas,Santiago Perez Hoyos,CoRIS-MD,Julia del Amo,Jesús Castila,José Antonio Iribarren,Santíago Moreno,Santíago Pérez-Hoyos,Maria Angeles Rodríguez Arenas,J Arrizabalaga,M J Aramburu,X Camino,F Rodriguez-Arrondo,M A von Wichmann,Maria Jesús Pérez-Elias,Jose Luis Casado Osorio,Ana Moreno Zamora,Luis Fernando Lopez-Cortés,Mónica Trastoy González,Rosario Mata Alcazar-Caballero,Federico García,Jorge Parra,Alejandro Peña,José Hernández Quero,M Remedios Alemán Valls,M del Mar Alonso Socas,Carlos Hernánadez,Maria Saumoy,Cristóbal Richart,José Lacruz,Cristina Falcó Couchoud,Marino Blanes Juliá,Vicente Navarro Ibáñez,Miguel Salavert Lletí,Enrique Bernal,Valvanera Ibara,José Antonio Oteo,Román Asensío
DOI: https://doi.org/10.1371/journal.pone.0000089
IF: 3.7
2006-12-20
PLoS ONE
Abstract:Background: Limited information exists on long-term prognosis of patients with sustained virologic response to antiretroviral therapy. We aimed to assess predictors of unfavorable clinical outcome in patients who maintain viral suppression with HAART. Methods: Using data collected from ten clinic-based cohorts in Spain, we selected all antiretroviral-naive adults who initiated HAART and maintained plasma HIV-1 RNA levels <500 copies/mL throughout follow-up. Factors associated with disease progression were determined by Cox proportional-hazards models. Results: Of 2,613 patients who started HAART, 757 fulfilled the inclusion criteria. 61% of them initiated a protease inhibitor-based HAART regimen, 29.7% a nonnucleoside reverse-transcriptase inhibitor-based regimen, and 7.8% a triple-nucleoside regimen. During 2,556 person-years of follow-up, 22 (2.9%) patients died (mortality rate 0.86 per 100 person-years), and 40 (5.3%) died or developed a new AIDS-defining event. The most common causes of death were neoplasias and liver failure. Mortality was independently associated with a CD4-T cell response <50 cells/L after 12 months of HAART (adjusted hazard ratio [AHR], 4.26 [95% confidence interval {CI}, 1.68-10.83]; P = .002), and age at initiation of HAART (AHR, 1.06 per year; 95% CI, 1.02-1.09; P = .001). Initial antiretroviral regimen chosen was not associated with different risk of clinical progression. Conclusions: Patients with sustained virologic response on HAART have a low mortality rate over time. Long-term outcome of these patients is driven by immunologic response at the end of the first year of therapy and age at the time of HAART initiation, but not by the initial antiretroviral regimen selected.